Are the Economics of Pharmaceutical Research and Development Changing?
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 22 (Supplement) , 15-24
Abstract
Pharmaceutical research and development (R&D) competition in the 1980s and 1990s was characterised by rising R&D expenditures, favourable returns to innovators and the introduction of many new classes of drugs with high social benefits. However, in the past 3 years, the number of new drug introductions has been well below the historical trend, while the cost per new drug continues to increase. In addition to lagging R&D productivity, the industry has been characterised by other economic and policy uncertainties. These include a wave of early patent challenges and growing political pressure to contain pharmaceutical expenditures. This paper examines the consequences of these developments.Keywords
This publication has 7 references indexed in Scilit:
- Medicare Drug Coverage And Moral HazardHealth Affairs, 2004
- Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Returns on Research and Development for 1990s New Drug IntroductionsPharmacoEconomics, 2002
- The Link Between Gross Profitability And Pharmaceutical R&D SpendingHealth Affairs, 2001
- Longer Patents for Increased Generic Competition in the USPharmacoEconomics, 1996
- Research and Development Costs and Returns: The U.S. Pharmaceutical IndustryJournal of Political Economy, 1972